CCM
AXDX

Cadian Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Cadian Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,947
Closed -$678K – 56
2020
Q4 		$678K Hold
8,947
– – 0.02% 34
2020
Q3 		$954K Buy
+8,947
New +$1.24M 0.03% 26
2019
Q3 		– Sell
-1,683
Closed -$385K – 27
2019
Q2 		$385K Sell
1,683
-28,116
-94% -$5.5M 0.02% 28
2019
Q1 		$6.26M Buy
+29,799
New +$5.59M 0.24% 29

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Cadian Capital Management's AXDX Position: Q1 2021 in Review

Cadian Capital Management sold out of Accelerate Diagnostics (AXDX) in Q1 2021, closing a stake of 8,947 shares — an estimated $678K sold.

Cadian Capital Management first reported a position in AXDX in Q1 2019 and held it in 4 quarters. The position peaked at $6.26M in Q1 2019. 99 funds tracked by Wall St. Rank hold AXDX as of Q1 2021.

  • Cadian Capital Management reported no remaining Accelerate Diagnostics position as of Q1 2021 after selling out during the quarter.
  • Cadian Capital Management sold 8,947 Accelerate Diagnostics shares in Q1 2021, an estimated $678K.
  • Cadian Capital Management first reported a position in Accelerate Diagnostics in Q1 2019 and held it in 4 quarters.
  • Cadian Capital Management's Accelerate Diagnostics position peaked at $6.26M in Q1 2019.
  • 99 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2021.

Based on Cadian Capital Management's 13F filing for Q1 2021, filed 14 May 2021.